{"id":821638,"date":"2025-03-04T16:17:01","date_gmt":"2025-03-04T21:17:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\/"},"modified":"2025-03-04T16:17:01","modified_gmt":"2025-03-04T21:17:01","slug":"viking-therapeutics-to-participate-at-upcoming-investor-conferences-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\/","title":{"rendered":"Viking Therapeutics to Participate at Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">SAN DIEGO<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">March 4, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0Viking Therapeutics, Inc. (&#8220;Viking&#8221;) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today\u00a0announced that the company will participate at multiple upcoming investor conferences.\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg\" title=\"Viking Therapeutics (PRNewsfoto\/Viking Therapeutics, Inc.)\" alt=\"Viking Therapeutics (PRNewsfoto\/Viking Therapeutics, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Details of the company&#8217;s participation are as follows:<\/p>\n<ul type=\"disc\">\n<li>\n          <b>Leerink Partners Global Healthcare Conference 2025<br \/><\/b>Details: Viking management will participate in a fireside chat and in 1-on-1 meetings<br \/>Conference Date: <span class=\"xn-chron\">March 10-12, 2025<\/span><br \/>Fireside Chat Timing: 9:20 \u2013 <span class=\"xn-chron\">9:50 a.m.<\/span> Eastern on <span class=\"xn-chron\">Tuesday, March 11, 2025<\/span><br \/>Location: <span class=\"xn-location\">Miami, FL<\/span><\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <b>Jefferies Biotech on the Beach Summit<br \/><\/b>Details: Viking management will participate in 1-on-1 meetings<br \/>Conference Dates: <span class=\"xn-chron\">March 11-12, 2025<\/span><br \/>Location: <span class=\"xn-location\">Miami, FL<\/span><\/li>\n<\/ul>\n<p>A live webcast of the Leerink presentation may be accessed via a link on the Viking Therapeutics website in the Investors &amp; Media section under\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4374460-1&amp;h=3037192689&amp;u=http%3A%2F%2Fir.vikingtherapeutics.com%2Fwebcasts&amp;a=Webcasts\" target=\"_blank\" rel=\"nofollow\">Webcasts<\/a>. Additionally, a replay of the webcast will be available on the Viking website following the conference.\u00a0<\/p>\n<p>\n        <b>About Viking Therapeutics, Inc. <\/b>\n      <\/p>\n<p>Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials.\u00a0Viking&#8217;s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients&#8217; lives.\u00a0Viking&#8217;s clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 1 trial. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a recently completed Phase <span class=\"xn-money\">2b<\/span> study for the treatment of biopsy-confirmed non-alcoholic\u00a0steatohepatitis (NASH) and fibrosis.\u00a0In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo.\u00a0The company&#8217;s newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase\u00a01b\u00a0clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.<\/p>\n<p>For more information about Viking Therapeutics, please visit\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4374460-1&amp;h=1098763188&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4197323-1%26h%3D4201129706%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4124488-1%2526h%253D3719708903%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3866590-1%252526h%25253D4076357968%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3821369-1%25252526h%2525253D1599847740%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D3586345-1%2525252526h%252525253D65010134%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D3117978-1%252525252526h%25252525253D1140731627%252525252526u%25252525253Dhttp%2525252525253A%2525252525252F%2525252525252Fwww.vikingtherapeutics.com%2525252525252F%252525252526a%25252525253Dwww.vikingtherapeutics.com%2525252526a%252525253Dwww.vikingtherapeutics.com%25252526a%2525253Dwww.vikingtherapeutics.com%252526a%25253Dwww.vikingtherapeutics.com%2526a%253Dwww.vikingtherapeutics.com%26a%3Dwww.vikingtherapeutics.com&amp;a=www.vikingtherapeutics.com\" target=\"_blank\" rel=\"nofollow\">www.vikingtherapeutics.com<\/a>.<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA31859&amp;sd=2025-03-04\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-302390478.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-302390478.html<\/a><\/p>\n<p>SOURCE  Viking Therapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA31859&amp;Transmission_Id=202503041605PR_NEWS_USPR_____LA31859&amp;DateId=20250304\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN DIEGO , March 4, 2025 \/PRNewswire\/ &#8212;\u00a0Viking Therapeutics, Inc. (&#8220;Viking&#8221;) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today\u00a0announced that the company will participate at multiple upcoming investor conferences.\u00a0 Details of the company&#8217;s participation are as follows: Leerink Partners Global Healthcare Conference 2025Details: Viking management will participate in a fireside chat and in 1-on-1 meetingsConference Date: March 10-12, 2025Fireside Chat Timing: 9:20 \u2013 9:50 a.m. Eastern on Tuesday, March 11, 2025Location: Miami, FL Jefferies Biotech on the Beach SummitDetails: Viking management will participate in 1-on-1 meetingsConference Dates: March 11-12, 2025Location: Miami, FL A live webcast of the Leerink presentation may be accessed via a link on the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Viking Therapeutics to Participate at Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-821638","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Viking Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viking Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO , March 4, 2025 \/PRNewswire\/ &#8212;\u00a0Viking Therapeutics, Inc. (&#8220;Viking&#8221;) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today\u00a0announced that the company will participate at multiple upcoming investor conferences.\u00a0 Details of the company&#8217;s participation are as follows: Leerink Partners Global Healthcare Conference 2025Details: Viking management will participate in a fireside chat and in 1-on-1 meetingsConference Date: March 10-12, 2025Fireside Chat Timing: 9:20 \u2013 9:50 a.m. Eastern on Tuesday, March 11, 2025Location: Miami, FL Jefferies Biotech on the Beach SummitDetails: Viking management will participate in 1-on-1 meetingsConference Dates: March 11-12, 2025Location: Miami, FL A live webcast of the Leerink presentation may be accessed via a link on the &hellip; Continue reading &quot;Viking Therapeutics to Participate at Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-04T21:17:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Viking Therapeutics to Participate at Upcoming Investor Conferences\",\"datePublished\":\"2025-03-04T21:17:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\\\/\"},\"wordCount\":497,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/273590\\\/viking_9_15_logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\\\/\",\"name\":\"Viking Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/273590\\\/viking_9_15_logo.jpg\",\"datePublished\":\"2025-03-04T21:17:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/273590\\\/viking_9_15_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/273590\\\/viking_9_15_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Viking Therapeutics to Participate at Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Viking Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\/","og_locale":"en_US","og_type":"article","og_title":"Viking Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk","og_description":"PR Newswire SAN DIEGO , March 4, 2025 \/PRNewswire\/ &#8212;\u00a0Viking Therapeutics, Inc. (&#8220;Viking&#8221;) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today\u00a0announced that the company will participate at multiple upcoming investor conferences.\u00a0 Details of the company&#8217;s participation are as follows: Leerink Partners Global Healthcare Conference 2025Details: Viking management will participate in a fireside chat and in 1-on-1 meetingsConference Date: March 10-12, 2025Fireside Chat Timing: 9:20 \u2013 9:50 a.m. Eastern on Tuesday, March 11, 2025Location: Miami, FL Jefferies Biotech on the Beach SummitDetails: Viking management will participate in 1-on-1 meetingsConference Dates: March 11-12, 2025Location: Miami, FL A live webcast of the Leerink presentation may be accessed via a link on the &hellip; Continue reading \"Viking Therapeutics to Participate at Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-04T21:17:01+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Viking Therapeutics to Participate at Upcoming Investor Conferences","datePublished":"2025-03-04T21:17:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\/"},"wordCount":497,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\/","name":"Viking Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg","datePublished":"2025-03-04T21:17:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Viking Therapeutics to Participate at Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/821638","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=821638"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/821638\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=821638"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=821638"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=821638"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}